This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Results
In the base case, the mean QALYs gained were 0.036 (95% CI -0.001 to 0.074) with mometasone furoate and 0.053 (95% CI 0.019 to 0.086) with placebo. The mean costs were £454 (95% CI 284 to 623) with mometasone furoate and £442 (95% CI 314 to 571) with placebo. Placebo (no active treatment) was dominant over the topical steroid, as it was less costly and more effective.
There was substantial uncertainty around this result. In 46% of the bootstrap replications, the intervention group was less costly than placebo, and in 24% topical steroids generated more QALYs. At a £20,000 per QALY threshold, the intervention was cost-effective in 24.19% of replications.
Using the utilities from the HUI2 or the EQ-5D, the intervention was cost-effective, with an incremental cost-utility ratio of less than £3,000 per QALY. Topical steroids were cost-effective, compared with placebo, in 63.20% of replications with the HUI2 and 88.66% with the EQ-5D. There were no subgroups in which topical steroids were costeffective in more than 45% of replications at the £20,000 per QALY threshold.
The EVPI was £65.73 per child or £9.1 million for the 160,000 children in the UK who were potentially eligible for treatment over the next 10 years. This EVPI was higher than the cost of many trials, which suggested that it might be cost-effective to collect further evidence on the efficacy and cost-effectiveness of steroids for OME.
